Make an enquiry
Refer a patient
Patient Portal
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

US
UK
ES
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

US
UK
ES
Find a centre
Find a doctor
2018-11-22T00:00:00.000+08:00

Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer

Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer
https://pubmed.ncbi.nlm.nih.gov/30473431/
Theranostics
Written by Heck M; Tauber R; Schwaiger S et al.;
Heck M; Tauber R; Schwaiger S et al.;:::